• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Lensar announces FDA acceptance of 510(k) submission for adaptive cataract treatment system


The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

Lensar Inc. today announced that the FDA has accepted the 510(k) submission for its next-generation adaptive cataract treatment system (ALLY) for substantive review.

The submission seeks marketing clearance for the system and is the first stage of a planned, two step commercial release strategy. As part of this strategy, the company said in a news release that it plans to submit an additional 510(k) application seeking clearance for the phacoemulsification features within the integrated system later in 2022.

In the release, Nick Curtis, CEO of Lensar, noted that FDA acceptance for substantive review of the 510(k) submission for the surgical system marks an important milestone for the company and is the result of several years of diligent teamwork and focused effort on the part of its development team.

“We believe that, if ALLY is cleared by the FDA, this staged-approach would allow for an expeditious and efficient path to commercialization,” Curtis said in a statement. “The vast majority of cataract surgeons performing FLACS procedures rely on aging femtosecond lasers.”

Curtis also pointed out that system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools which if cleared, company officials believe would set the new standard of femtosecond laser cataract technology.

“We believe ALLY has the potential to improve surgeon efficiencies, including optimizing FLACS procedures in any operating room, and to enable surgeons to deliver improved outcomes for patients,” he said in the statement. “We look forward to the FDA’s review of the 510(k).”

According to the news release, the company said it expects to launch the surgical system in the second half of 2022, if cleared.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.